ClinicalTrials.gg
RecruitingNCT07012629EURO-CBIUpdated Dec 4, 2025

A EUROpean Randomized Study on Blood-thinners and Cholesterol-lowering Treatments to Prevent Future Vascular Events in People With Covert Brain Infarcts (CBI)

A Phase 3 interventional study of acetylsalicyclic acid (ASA) and Clopidogrel in Covert Brain Infarction, sponsored by Aarhus University Hospital. Recruiting at 14 sites in 5 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-12-04.

Sponsored by Aarhus University Hospital · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,652
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Dementia with a site in Denmark — 6 open to participants now, 12 under way, 1 of them phase 3. Dementia · Denmark.

Planned enrollment
3rd of 21
1,652 · median 339
Started
2025
with 5 others
Phase 3
4 of 30
1 open now
Primary completion
2031-09
later than 11 of 11 live
Registered
23rd of 30
by date
Lead sponsor
2 of 30
Aarhus University Hospital

Among the 30 studies in Dementia with a site in Denmark, this one is the 3rd largest by planned enrollment of the 21 interventional ones that give a count, is one of 6 that started in 2025, is one of 4 in phase 3, reaches primary completion later than 11 of the 11 other live ones, and was the 23rd registered.

Dementia

2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.

Browse Dementia studies →

Open to participants now

6 of the 30 studies in Dementia with a site in Denmark are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Dementia with a site in Denmark, or all of them as a file.
02

Study summary

Magnetic resonance imaging (MRI) is commonly used in healthcare, and sometimes it shows small areas of brain damage called Covert Brain Infarcts (CBIs). These are usually found by chance when people have scans for things like headaches or dizziness. Although CBIs don't cause symptoms at the time, they are linked to a higher risk of future stroke and death.

There is currently no standard treatment for CBIs, and doctors have different approaches-some give stroke-preventing medication (like antiplatelets or statins), while others don't treat at all. This is mostly because there isn't enough research yet.

This study will test whether stroke-preventing treatments help people with CBIs. It will also look at whether having a CBI increases the risk of dementia, and whether treatment might lower that risk.

03

Conditions studied

  • Covert Brain Infarction

Browse trials for

Keywords

  • CBI
  • Prevention
  • Asymptomatic brain infarction
  • Dementia
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • MRI demonstrating a lacunar infarct (acute/subacute/chronic) without prior stroke/ symptoms. (A round or ovoid, subcortical, fluid-filled cavity (signal similar to cerebrospinal fluid (CSF)) between 3 and 15 mm in diameter and demonstrating a peripheral T2/FLAIR hyperintense rim of marginal gliosis. For infratentorial lesions the hyperintense rim may be less marked and a complete ring is not required) OR
  • MRI demonstrating a cortical infarct (acute/subacute/chronic) without prior stroke/TIA symptoms (A cortical infarct is defined as a fluid-filled cavity (signal similar to CSF) in the cortex, juxtacortical region or cerebellar cortex and with a ring of T2/FLAIR hyperintense lesions or as cortical T2/FLAIR lesions without a fluid-filled cavity with presumed vascular origin. Both supra- and infratentorial lesion will be included) AND > 12 months AND Predominantly independent in actives of daily living (mRS score ≤ 3) AND Age ≥ 50 years

Exclusion criteria

Exclusion Criteria:

  • History of stroke/
  • High risk of bleeding (e.g., recent or recurrent gastrointestinal or genitourinary bleeding associated with a decrease in levels of at least 1 mmol/L, active peptic ulcer disease, MRI with cortical siderosis and/or prior lobar hemorrhage)
  • Indication for long-term use of anticoagulants (e.g. deep vein thrombosis, pulmonary embolism, atrial fibrillation, and rarer indications; such as mechanical heart valve, antiphospholipid antibody syndrome etc.)
  • Concurrent indication for lipid-lowering treatment and/or -inhibitors for secondary cardiovascular prevention (ischemic heart disease, recent stenting, ischemic stroke, revascularization surgeries, lower-extremity atherosclerotic arterial disease etc.)
  • Co-existing progressive neurodegenerative disease including dementia or Parkinson's disease.
  • Neoplastic condition that is uncontrolled or associated with an increased risk of bleeding
  • Patient already on antiplatelet or anticoagulation agent, regardless of indication
  • Women with a history of menopause below 12 months are only included after negative pregnancy test
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Single (Outcomes assessor)
Enrollment
1,652 participants (estimated)

Study arms

  • Experimental
    Group A: Platelet inhibitor - no Statin ("APT alone")

    All patients will initiate treatment with Aspirin or Clopidogrel. The decision on which of the two drugs to initiate is at the discretion of the treating physician/center.

    Drug: acetylsalicyclic acid (ASA) · Drug: Clopidogrel

  • Experimental
    Group B: Statins - no Platelet inhibitor ("Statin alone").

    Patients will be treated with high-intensity statin therapy (Atorvastatin 40 mg once daily or Rosuvastatin 20 mg once daily)

    Drug: Rosuvastatin · Drug: Atorvastatin

  • Experimental
    Group C: Statins - Platelet inhibitor ("APT AND statin")

    Both types of medication are initiated as described in group A and B

    Drug: acetylsalicyclic acid (ASA) · Drug: Clopidogrel · Drug: Rosuvastatin · Drug: Atorvastatin

  • No intervention
    Group D: No Statins - no Platelet inhibitor (current standard treatment)

    This group follows the current European recommendations of primary prevention which do not include statins and APT agents. If statins and/or platelet inhibitors are started during the study-period it should adhere to primary prevention guidelines. All four groups receive advice on lifestyle optimization and blood pressure management.

Interventions

  • DrugAspirinStudies of AspirinAspirin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Daily dose 75 mg to 100 mg p.o.

    Also known as: Aspirin

  • Daily dose 75 mg p.o.

  • Daily dose 20 mg p.o. (10 mg once daily for the first 4 weeks, then 20 mg once daily for the remainder of the study period if tolerated). If Rosuvastatin 20 mg is not tolerated, a dose reduction to 10 mg is allowed.

  • Daily dose 40 mg p.o. If Atorvastatin 40 mg is not tolerated, a dose reduction to 20 mg is allowed.

06

What researchers measure

Primary outcomes

  1. Major Adverse Cardiac and Cerebral Events (MACCE) at 12 and 36 months

    MACCE are defined as the occurrence of any of the following events * All cause death: Death from any cause * Acute myocardial infarction: Admission with a discharge diagnosis of ST-elevation myocardial infarction (STEMI) and non-ST elevation myocardial infarction (NSTEMI) and * Stroke: AIS\* or Intracerebral hemorrhage (non-traumatic) \*Including Transient Ischemic Attack (TIA) with evidence of brain tissue infarction i.e. remission of symptoms within 24 hours but who have an acute ischemic lesion on diffusion weighted imaging MRI. All events qualifying for a MACCE event will be adjudicated by the Clinical event committee. Accepted timeframe for evaluation is +/- 30 days

    Time frame: 12 months and 36 months post-randomization.

  2. Major and fatal bleeding at 12 and 36 months

    Major and fatal bleeding events are defined according to criteria established by the International Society on Thrombosis and Haemostasis (ISTH): * Fatal bleeding, and/or * Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, or intramuscular with compartment syndrome, and/or * Bleeding leading to a drop in hemoglobin of ≥20 g/L (1.24 mmol/L), or requiring transfusion of two or more units of whole blood or red cells. All qualifying events will be adjudicated by an independent Clinical Event Committee (CEC). The accepted time window for assessment is ±30 days.

    Time frame: 12 months and 36 months post-randomization.

Secondary outcomes

  1. All-cause dementia

    Dementia is identified through phone contact and review of the patient's electronic health record, based on national diagnostic standards. Accepted diagnoses align with ICD-10 and ICD-11. ICD-10 codes include: dementia in Alzheimer's disease (F00.0-F00.9, DG30.0-DG30.9), vascular dementia (F01.0-F01.9, F00.2), dementia in other diseases classified elsewhere (F02.0-F02.8), unspecified dementia (F03.9), Lewy body dementia (DG31.8E), progressive isolated aphasia (DG31.0A), Pick disease (DG31.0B), and unspecified degenerative disease of the nervous system (DG31.9). ICD-11 codes include: dementia due to Alzheimer's disease (6D80), cerebrovascular disease (6D81), Lewy body disease (6D82), frontotemporal dementia (6D83), other specified diseases (6D85.Y), and dementia of unknown or unspecified cause (6D8Z). The accepted time window for evaluation is ±30 days.

    Time frame: 12 months and 36 months post-randomization.

  2. Cardiovascular-related mortality

    Information about cardiovascular mortality is collected from telephone contacts and from the patient's electronic health record. See the table below for the definition of cardiovascular mortality. Cardiovascular Mortality are defined as: * Acute MI * Sudden cardiac death * Heart failure * Stroke: death as a direct consequence or complication of stroke * Cardiovascular procedure * Cardiovascular-related haemorrhage: non-stroke intracranial haemorrhage (subdural hematoma), non-procedural or non-traumatic vascular rupture (e.g. aortic aneurysm), or haemorrhage causing cardiac tamponade * Death due to other cardiovascular causes: a cardiovascular death not included in the above categories but with a specific, known cause (e.g., pulmonary embolism or peripheral arterial disease) Accepted time for evaluation is +/- 30 days

    Time frame: 12 months and 36 months post-randomization.

  3. Cognitive decline

    A significant cognitive decline, defined as a ≥2-point reduction in Montreal Cognitive Assessment (MoCA) scores at 36 months. The participant's score on the full 12 item in-person MoCA (30 points) at the initial visit is compared to the scores on the telephone administrated Tele-MoCA (items from MoCA not requiring the use of a pencil and paper or visual stimulus, maximum of 22 points) after 12 and 36 months. Accepted time for evaluation is +/- 30 days

    Time frame: After 12 months and a end of treatment at 36 months

  4. Serious adverse event (SAE)

    Information on SAEs will be reported by the investigators and recorded in the eCRF.

    Time frame: From enrollment to the end of treatment at 36 months

  5. Baseline MRI risk markers, quantified using the ordinal simplified SVD-score (small vessel disease) score

    Simple SVD defined as score: Microbleeds: 0 microbleeds = 0 point; ≥ 1 microbleed = 1 point White matter hyperintensities (Fazekas): Fazekas 0-1 = 0 point; Fazekas 2-3 = 1 point. Lacunes: 0-2 lacunes = 0 point; \>2 lacunes = 1 point. Total SVD score (range): 0-3.

    Time frame: After 12 months and at the end of treatment at 36 months

  6. Physical activity levels

    Baseline physical activity levels are measured by the International Physical Activity Questionnaire (IPAQ).It yields a categorical score: low, moderate, or high level of physical activity. The follow-up assessment will be performed by staff from the enrolling site. Accepted time for evaluation is +/- 30 days

    Time frame: At baseline

  7. Modified Rankin Scale (mRS) score

    The change in mRS score will be assessed to evaluate shifts in functional independence and disability over time. The mRS ranges from 0 to 6, with higher scores indicating worse outcomes. The follow-up assessment at 12 and 36 months will be performed by staff from the enrolling site. Accepted time for evaluation is +/- 30 days

    Time frame: From baseline to 12 months and to the end of treatment at 36 months

  8. Clinical Frailty Scale (CFS) score

    The change in CFS score will be assessed from baseline to 12 and 36 months to evaluate the progression of frailty and its impact on functional status and overall health over time. It ranges from 1 to 9, with 1 indicating "very fit" and 9 indicating "terminally ill." The follow-up assessments at 12 and 36 months will be performed by staff from the enrolling site Accepted time for evaluation is +/- 30 days

    Time frame: From baseline to 12 months and to the end of treatment at 36 months

  9. Barthel Index (BI) for Activities of Daily Living (ADL)

    The Barthel Index is a score that describes the degree of independence in relation to assistance from another person. It ranges from 0 to 100, with higher scores indicating greater independence. A score close to 100 reflects that the individual is self-sufficient, whereas lower scores indicate increasing dependence on others in daily activities. A score near 0 typically suggests that the individual is bedridden and requires help with all tasks. The follow-up assessments at 12 and 36 months will be performed by staff from the enrolling site. Accepted time for evaluation is +/- 30 days

    Time frame: From enrollment to 12 months and to the end of treatment at 36 months

  10. Quality of life (EQ-5D)

    The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. The follow-up assessments at 12 and 36 months will be performed by staff from the enrolling site. Accepted time for evaluation is +/- 30 days

    Time frame: From enrollment to 12 months and to the end of treatment at 36 months

  11. CBI subtype

    The CBI subtype and infarct appearance will be described by the enrolling physician, who has been trained to identify these findings on MRI. The baseline MRI will be visually graded by the investigators and the total SVD score calculated. The DICOM (Digital Imaging and Communications in Medicine) file containing the MRI will be downloaded and uploaded to the electronic case report form (eCRF) at redcap.au.dk, for later assessment by an imaging core lab.

    Time frame: At baseline

Other outcomes

  1. MRI-based assessment of small vessel disease progression (sub-study)

    At centers participating in the extended imaging sub-study, patients will be invited to a follow-up MRI after 3 years (+/- 1 months). The baseline MRI should be of sufficient quality and with a field strength of 3 Tesla. The follow-up MRI will contain diffusion-weighted imaging, apparent diffusion coefficient, Susceptibility Weighted Imaging (preferred) or T2\* gradient-recalled echo, and T2 fluid-attenuated inverse recovery. Newly developed lacunar and/or cortical infarctions will be recorded and a SVD score will be calculated. If possible T1 weighted sequences will be performed. The MRI will be uploaded to eCRF. The number of CBIs, number of cerebral microbleeds, deep white matter lesions (Fazekas grade), MRI SVD score, and Global Cortical Atrophy (GCA) Scale will be assessed by two blinded assessors. If there is disagreement, a third and final blinded assessor will perform the assessment.

    Time frame: After 36 months (+/- 1 months)

  2. MRI-based assessment of white matter lesion (WML) volume growth

    WML volume will be estimated using semiautomatic software, such as 3D Slicer (an open-source medical image analysis tool) or a similar alternative. WML will be segmented together with volume quantification. It will be performed by two blinded assessors, and the final volume will represent a consensus volume between the assessors.

    Time frame: 36 months (+/- 1 month)

  3. Carotid plaque quantification on ultrasound

    At centers participating in the extended imaging sub-study, patients will be invited to an ultrasound examination at the baseline visit. The common- and internal carotid artery will be assessed for signs of atherosclerotic disease and presence, size and morphology of plaques, classifying them based on echogenicity (homogeneous or heterogeneous), surface characteristics (smooth or irregular), and calcification (presence or absence) ipsilateral to the CBI. If bilateral CBIs are present, the left side will be scanned. A plaque score will be calculated based on sum scores for each plaque identified in the carotid and intracranial arteries based on size and morphology. Plaque Grading Consensus will be used and range from no plaque (IMT \< 1.5mm), protuberant/diffuse \< 1.5mm IMT, protuberant/ diffuse with IMT 1.5-2.4mm or protuberant/ diffuse with IMT \>2.5mm.

    Time frame: At baseline

  4. Pulsatility index on ultrasound

    Pulsatility Index (PI) of the mid- and distal middle cerebral artery (MCA) will be measured using transcranial Doppler ultrasound to assess blood flow resistance within cerebral vessels. It will be calculated based on the difference between peak systolic and end-diastolic blood flow velocities relative to the mean flow velocity: PI=(Peak Systolic Velocity-End-Diastolic Velocity)/Mean Velocity. PI has been associated with increased microvascular resistance, white matter disintegration, plaque burden.

    Time frame: At baseline

07

Study locations

1 of 14 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data underlying the baseline screening visit and 3 years outcome can be shared after de-identification, upon reasonable request and proposals should be directed at the principal study investigator. To gain access to these data, data requestors will need to sign a data processing agreement. Further, anonymized data will be available through public databases such as the Zenodo open data repository (CERN) or other equivalent databases after trial completion.

Supporting information: Study protocol, Statistical analysis plan

Time frame: After publication of the primary endpoint (estimated Sept 30, 2032)

Access criteria: To gain access to these data, data requestors will need to sign a data processing agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Sep 2031, 70 months after the start.

Of 34 phase 3 interventional studies under Dementia, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 60. This study's planned 70 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2025
First posted
Jun 10, 2025
StartActual
Nov 26, 2025
Primary completionEst.
Sep 30, 2031
CompletionEst.
Jan 1, 2040
Last update
Dec 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07012629
Responsible party
Rolf Blauenfeldt (MD, PhD, Associate professor of Neurology., Aarhus University Hospital) — Principal investigator
First posted
Jun 10, 2025
Start date
Nov 26, 2025
Primary completion
Sep 30, 2031 (estimated)
Completion
Jan 1, 2040 (estimated)
Last update
Dec 4, 2025

Study contacts

Rolf Blauenfeldt
Contact
rolfblau@rm.dk
+4529318244
Ida Thingholm Norup
Contact
idnoru@rm.dk
+4520848978

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aspirin · Clopidogrel · Rosuvastatin · Atorvastatin

Start the discussion